Aranesp

Procrit and Aranesp for aplastic anemia – pro

Is aranesp considered medically necessary for aplastic anemia? Erythropoietin levels are elevated in apalstic anemia patients. This raises the probability that additional exogenous erythropoietin may not be effective. However, despite the same concern, erythropoietin is effective inĀ  in myelodysplastic syndrome. I reference a Japanese editorial that advocated the use of erythropoietin ( and this would include darbepoetin) for aplastic anemia. However,

Read more
Aranesp intravenously – pro

Lay Sumamry: Aranesp intravenously works as well as by injection under the skin. Darebpoietin is FDA approved for sq administration unlike erytrhopoietin. However, there are situations in which IV adminsitration is more convenient for the patient, such as, for example, when there is on onging IV line for another reason. The two most common settings of this kind are the neonates and patients on dyalisis. The treatment of renal anaemia using erythropoiesis

Read more
Erytropoietin therapy for myelofibrosis – pro

Experience with recombinant human erythropoietin (rHuEPO) in the treatment of the anemia secondary to myelofibrosis with myeloid metaplasia (MMM) is limited.There are a number of reports of small numbers of patiens demonstrating responsiveness but also a recent reportĀ  which presents a picture of non-responsiveness of transfusion dependent myelofibrosis to erythropoietin therapy. Initial studies failed to show significant improvements in hemoglobin

Read more
Procrit, Aranesp and G-CSF for myelodysplasia – pro

Treatment of anemia with recombinant human erythropoietin (rHuEPO) alone is effective only in a small percentage of MDS patients. A meta-analysis of 205 patients with MDS showed that 16% responded to rHuEPO alone.Patients with a transfusion need of < 2 units per month and a serum erythropoietin concentration of < 500 U/l had a 74% response rate to combined erythropoietin/G-CSF compared to a response rate of 23% and 7% for those patients with

Read more